Several factors have been found to affect engraftment after autologous SCT (ASCT) in multiple myeloma (MM), including source of stem cells, number of infused CD34+ cells, prior use of myelotoxic agents and use of haematopoietic growth factors post ASCT. Recently, bisphosphonates were shown to delay haematological recovery after ASCT in mice when compared to untreated controls.
Several factors have been found to affect engraftment after autologous SCT (ASCT) in multiple myeloma (MM), including source of stem cells, number of infused CD34+ cells, prior use of myelotoxic agents and use of haematopoietic growth factors post ASCT. Recently, bisphosphonates were shown to delay haematological recovery after ASCT in mice when compared to untreated controls. 1 To the best of our knowledge, this has not been studied in the clinical setting. The aim of this study was to evaluate the impact of bisphosphonates on haematological recovery after ASCT in patients with MM. We analysed 207 myeloma patients transplanted in 1993-2010 whose data were prospectively collected in our institutional ASCT registry. There were 166 patients who had received bisphosphonate (clodronate, pamidronate or zoledronate) treatment before ASCT and 41 who had not. There was no difference in the recovery times of blood neutrophil and platelet counts between the two groups: blood neutrophils reached a count of 1.0 × 10 9 /L on days 11 and 11, and platelets a count of 20 × 10 9 /L on days 13 and 13, respectively (Table 1) . Similarly, no differences in engraftment times were seen in patients who had received clodronate, pamidronate or zoledronate. The patients were also divided into two groups on the basis of their therapy: Thal-Dex (n = 39, 74% bisphosphonate users) or vincristin, adriamycin, dexamethasone (n = 135, 78% bisphosphonate users). It appeared that the Thal-Dex group had delayed engraftment by a median of 3 days (P = 0.002, Table 1 ). In contrast to the bisphosphonate effect on engraftment after ASCT in mice, these drugs seem not to have a similar effect in myeloma in humans. Regarding the impact of the initial treatment on engraftment post ASCT, controversial results have been published. 2, 3 In our study, a delayed engraftment in patients previously treated with Thal-Dex was observed.
